Uncategorized

Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease

by Business Wire • 2020/10/22 • 0 Comments

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics raises US$20 million for registration studies for treatment of leading cause of dry eye disease.

Full Story →

← Santen joins forces with ophthalmologists in the fight against antibiotic resistance

Tarsus closes initial public offering →

Post navigation